biotech / news / / MarketScreener
Gilead Sciences is appealing lower court rulings that said about 24,000 patients using an HIV drug it produced can pursue negligence claims.
California's Supreme Court is skeptical about requiring drugmakers to develop safer alternatives by law.
KEY POINTS
- Gilead halted development of TAF in 2004, citing minimal difference from its existing TDF drug.
- Plaintiffs allege Gilead delayed TAF commercialization to coincide with TDF patent expiration in 2017.
- A ruling against Gilead could establish a 'duty to innovate' in product liability law.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →